NICE approves further treatment options for psoriatic arthritis

Certolizumab pegol (Cimzia) and secukinumab (Cosentyx) may be used within the NHS for the treatment of psoriatic arthritis when other drugs have been unsuccessful.

Certolizumab pegol and secukinumab are recommended by NICE as options for psoriatic arthritis. | SCIENCE PHOTO LIBRARY
Certolizumab pegol and secukinumab are recommended by NICE as options for psoriatic arthritis. | SCIENCE PHOTO LIBRARY

NICE guidance states that certolizumab pegol and secukinumab, alone or in combination with methotrexate, are recommended as options for the treatment of psoriatic arthritis in adults:

  • with at least 3 tender and 3 swollen joints who have responded inadequately to treatment with at least 2 DMARDs, given either alone or in combination, or
  • who have had an inadequate response (in the case of secukinumab) or lost response to a tumour necrosis factor (TNF) inhibitor after 12 weeks of treatment, or
  • in whom TNF inhibitors are contraindicated but would otherwise be considered (this applies to secukinumab only).

Certolizumab pegol blocks the activity of TNF, a major contributor to inflammation and joint damage, whereas secukinumab neutralises interleukin-17A (IL-17A), which could benefit patients intolerant to TNF inhibitors.

Treatment with certolizumab pegol and secukinumab should only be continued if there is an adequate response according to the Psoriatic Arthritis Response Criteria (PsARC; defined as an improvement in at least 2 of the 4 criteria, including joint tenderness or swelling, with no worsening in any criteria), at 12 weeks and 16 weeks respectively. For patients who achieve a Psoriasis Area and Severity Index (PASI) 75 response but not a PsARC response, a dermatologist should decide whether continuing treatment is appropriate.

In both cases the company must provide the drug within the discount agreed in the patient access scheme. Treatment of patients already receiving either drug may continue according to whatever funding arrangements were in place before the guidance was issued until the patient and their NHS clinician consider it appropriate to stop.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more